Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02722954 |
| Title | A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | OncoMed Pharmaceuticals, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | GBR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | United States | Details | |
| University of Michigan Health System | Ann Arbor | Michigan | 48109-5848 | United States | Details | |
| Columbia University Medical Center | New York | New York | 10032 | United States | Details | |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States | Details | |
| The START Center for Cancer Care | San Antonio | Texas | 78229 | United States | Details | |
| The Royal Marsden NHS Foundation Trust | Sutton | Surrey | SM2 5PT | United Kingdom | Details |